CMBA
ZNTL icon

C.M. Bidwell & Associates’s Zentalis Pharmaceuticals ZNTL Stock Holding History

C.M. Bidwell & Associates’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-436
Closed -$1.78K – 554
2024
Q2 		$1.78K Buy
+436
New +$4.87K ﹤0.01% 415

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

C.M. Bidwell & Associates's ZNTL Position: Q3 2024 in Review

C.M. Bidwell & Associates sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 436 shares — an estimated $1.78K sold.

C.M. Bidwell & Associates first reported a position in ZNTL in Q2 2024 and held it in 1 quarter. The position peaked at $1.78K in Q2 2024. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • C.M. Bidwell & Associates reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 436 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $1.78K.
  • C.M. Bidwell & Associates first reported a position in Zentalis Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Zentalis Pharmaceuticals position peaked at $1.78K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2024, filed 13 Nov 2024.